AHS 2022 | Future work on rimegepant for migraines

Richard Lipton, MD, Albert Einstein College of Medicine, New York, NY, discusses important future work on rimegepant for the treatment of migraine. Since rimegepant became available as a preventive medication recently, researchers and clinicians are still learning to use it in clinical practice. There is a need for more studies linking rimegepant to patient-reported outcome measures (PROMs), for more data demonstrating the consistency of the drug response when used as an acute treatment, and more data on how well it works as a preventive when combined with other preventive agents. Monotherapy may be efficient for some individuals, yet with many individuals having refractory headaches, more than one preventive may be required. This means there is a need for more data regarding drug-drug interactions between rimegepant and other oral medications. This interview took place during the 2022 American Headache Society (AHS) Annual Scientific Meeting in Denver, CO.